Microglia replacement halts the progression of microgliopathy in mice and humans

IF 45.8 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Science Pub Date : 2025-07-10 DOI:10.1126/science.adr1015

Jingying Wu, Yafei Wang, Xiaoyu Li, Pei Ouyang, Yuanyuan Cai, Yang He, Mengyuan Zhang, Xinghua Luan, Yuxiao Jin, Jie Wang, Yujie Xiao, Yuqing Liang, Fang Xie, Yousheng Shu, Jiong Hu, Chunkang Chang, Jieling Jiang, Dong Wu, Youshan Zhao, Taohui Liu, Yuxin Li, Xiaojun Huang, Yao Li, Junfang Zhang, Yuwen Cao, Xin Cheng, Ying Mao, Yanxia Rao, Li Cao, Bo Peng

{"title":"Microglia replacement halts the progression of microgliopathy in mice and humans","authors":"Jingying Wu, Yafei Wang, Xiaoyu Li, Pei Ouyang, Yuanyuan Cai, Yang He, Mengyuan Zhang, Xinghua Luan, Yuxiao Jin, Jie Wang, Yujie Xiao, Yuqing Liang, Fang Xie, Yousheng Shu, Jiong Hu, Chunkang Chang, Jieling Jiang, Dong Wu, Youshan Zhao, Taohui Liu, Yuxin Li, Xiaojun Huang, Yao Li, Junfang Zhang, Yuwen Cao, Xin Cheng, Ying Mao, Yanxia Rao, Li Cao, Bo Peng","doi":"10.1126/science.adr1015","DOIUrl":null,"url":null,"abstract":"<div >Colony-stimulating factor 1 receptor (<i>CSF1R</i>) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.</div>","PeriodicalId":21678,"journal":{"name":"Science","volume":"389 6756","pages":""},"PeriodicalIF":45.8000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science","FirstCategoryId":"103","ListUrlMain":"https://www.science.org/doi/10.1126/science.adr1015","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Colony-stimulating factor 1 receptor (CSF1R) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.

Abstract Image

查看原文本刊更多论文

小胶质细胞替代可以阻止小鼠和人类小胶质病变的进展

集落刺激因子1受体（CSF1R）主要在小胶质细胞中表达。它的单等位基因突变导致csf1r相关的小胶质病（CAMP），这是一种主要的成人发病的带有轴突球体和色素胶质的白质脑病（ALSP），是一种无法临床治愈的致命神经系统疾病。我们建立了包含人类CAMP热点突变的小鼠模型，并通过骨髓移植替代小胶质细胞（Mr BMT）将csf1r缺陷小胶质细胞替换为csf1r正常细胞，从而减轻了小鼠的病理。我们进一步证明，在CSF1R缺乏的情况下，ALSP患者的传统骨髓移植（tBMT）功能与Mr BMT相似，有效地替代小胶质细胞并减少疾病进展。然后，我们用tBMT替代了8名患者的csf1r缺陷小胶质细胞。在24个月的随访期间，疾病进展停止。总之，在小鼠和人类中，小胶质细胞替代纠正了致病突变并阻止了疾病的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Science 综合性期刊-综合性期刊

CiteScore

61.10

自引率

0.90%

发文量

审稿时长

2.1 months

期刊介绍： Science is a leading outlet for scientific news, commentary, and cutting-edge research. Through its print and online incarnations, Science reaches an estimated worldwide readership of more than one million. Science’s authorship is global too, and its articles consistently rank among the world's most cited research. Science serves as a forum for discussion of important issues related to the advancement of science by publishing material on which a consensus has been reached as well as including the presentation of minority or conflicting points of view. Accordingly, all articles published in Science—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by AAAS or the institutions with which the authors are affiliated. Science seeks to publish those papers that are most influential in their fields or across fields and that will significantly advance scientific understanding. Selected papers should present novel and broadly important data, syntheses, or concepts. They should merit recognition by the wider scientific community and general public provided by publication in Science, beyond that provided by specialty journals. Science welcomes submissions from all fields of science and from any source. The editors are committed to the prompt evaluation and publication of submitted papers while upholding high standards that support reproducibility of published research. Science is published weekly; selected papers are published online ahead of print.